Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$23.53 -1.3%	$22.18	$13.40 ▼ $25.23	$3.94B	0.7	1.63 million shs	1.75 million shs
ACLX Arcellx	$71.14 -0.4%	$66.67	$47.86 ▼ $107.37	$3.92B	0.28	404,218 shs	330,989 shs
AKRO Akero Therapeutics	$48.37 -1.0%	$52.04	$21.34 ▼ $58.40	$3.86B	-0.28	872,309 shs	867,371 shs
GPCR Structure Therapeutics	$17.59 -1.2%	$20.43	$13.22 ▼ $45.37	$1.01B	-1.89	728,968 shs	571,199 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+1.20%	+12.32%	+57.81%	+23.71%
ACLX Arcellx	0.00%	-0.24%	+5.71%	+8.53%	+15.09%
AKRO Akero Therapeutics	0.00%	-4.33%	-7.01%	+7.80%	+80.96%
GPCR Structure Therapeutics	0.00%	-1.95%	-14.69%	-35.07%	-52.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9839 of 5 stars	3.4	3.0	0.0	2.5	4.2	2.5
ACLX Arcellx	2.5874 of 5 stars	3.5	2.0	0.0	3.4	2.5	0.0
AKRO Akero Therapeutics	3.9572 of 5 stars	3.5	3.0	4.7	2.9	0.8	0.0
GPCR Structure Therapeutics	2.041 of 5 stars	3.5	1.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$28.13	19.53% Upside
ACLX Arcellx	3.07	Buy	$114.31	60.68% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	70.56% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	333.01% Upside

Current Analyst Ratings Breakdown

Latest GPCR, AKRO, ACLX, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$93.00 ➝ $133.00
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.11	$0.70 per share	33.38	$4.40 per share	5.35
ACLX Arcellx	$107.94M	36.32	N/A	N/A	$8.41 per share	8.46
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	17.18	30.96	6.54	22.97%	17.46%	10.75%	8/6/2025 (Estimated)
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)

Latest GPCR, AKRO, ACLX, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACLX Arcellx	-$1.03	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.95	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ACLX Arcellx	N/A	4.93	4.93
AKRO Akero Therapeutics	0.03	16.80	16.80
GPCR Structure Therapeutics	N/A	23.29	23.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ACLX Arcellx	96.03%
AKRO Akero Therapeutics	N/A
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ACLX Arcellx	8.35%
AKRO Akero Therapeutics	7.07%
GPCR Structure Therapeutics	9.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable

GPCR, AKRO, ACLX, and ACAD Headlines

Recent News About These Companies

Federated Hermes Inc. Sells 875,010 Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

August 2 at 5:13 AM | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

August 2 at 4:50 AM | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $76.17 Consensus Target Price from Brokerages

July 31 at 2:37 AM | americanbankingnews.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by Brokerages

July 28, 2025 | marketbeat.com

Readystate Asset Management LP Increases Stock Position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

July 22, 2025 | marketbeat.com

Principal Financial Group Inc. Lowers Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

July 13, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Trading Down 7.3% - Here's Why

July 7, 2025 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT

June 24, 2025 | msn.com

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 | globenewswire.com

Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous

June 10, 2025 | seekingalpha.com

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 9, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy Recommendation

May 3, 2025 | msn.com

Structure draws new Buy at Citi on oral obesity drug pipeline

May 2, 2025 | msn.com

Viking among notable gainers as Pfizer raises deal prospects

April 29, 2025 | msn.com

Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?

April 26, 2025 | msn.com

H.C. Wainwright maintains buy on Structure Therapeutics shares

April 24, 2025 | uk.investing.com

Researchers crack the code of cell movement

April 24, 2025 | sciencedaily.comS

Eli Lilly jumps as results from weight-loss pill study rival competitor’s

April 17, 2025 | markets.businessinsider.com

Why did Lilly data for oral GLP-1 boost Structure and Metsera?

April 17, 2025 | seekingalpha.com

SA Asks: What's the best weight-loss drug stock right now?

April 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, AKRO, ACLX, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$23.53 -0.30 (-1.26%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$23.17 -0.36 (-1.53%)

As of 08/1/2025 07:12 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx NASDAQ:ACLX

$71.14 -0.25 (-0.35%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$71.08 -0.06 (-0.08%)

As of 08/1/2025 05:13 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Akero Therapeutics NASDAQ:AKRO

$48.37 -0.48 (-0.98%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$48.32 -0.05 (-0.10%)

As of 08/1/2025 05:46 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Structure Therapeutics NASDAQ:GPCR

$17.59 -0.21 (-1.18%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$17.60 +0.02 (+0.09%)

As of 08/1/2025 04:32 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time